Delving into the Latest Updates on Total Glucosides of White Paeony with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

帕夫林

Target-

Action-

Mechanism-

Therapeutic Areas

Immune System DiseasesSkin and Musculoskeletal Diseases

Active Indication

Rheumatoid Arthritis

Inactive Indication-

Originator Organization

Ningbo Liwah Pharmaceutical Co. Ltd.

Active Organization

Ningbo Liwah Pharmaceutical Co. Ltd.

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

China (04 Jan 2020),

Rheumatoid Arthritis

Regulation-

Login to view timeline

To observe the safety, tolerability, and pharmacokinetic characteristics of single and multiple oral administration of different doses of total glucosides of white paeony capsules in healthy Chinese people, and to observe the possible dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) in the set dose groups.

Start Date10 Aug 2020

Sponsor / Collaborator

Ningbo Liwah Pharmaceutical Co. Ltd.

100 Clinical Results associated with Total Glucosides of White Paeony

Login to view more data

100 Translational Medicine associated with Total Glucosides of White Paeony

Login to view more data

100 Patents (Medical) associated with Total Glucosides of White Paeony

Login to view more data

100 Deals associated with Total Glucosides of White Paeony

Login to view more data

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Rheumatoid Arthritis	China	Ningbo Liwah Pharmaceutical Co. Ltd.	04 Jan 2020

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ChiCTR-TRC-12002325 (EULAR2016)	Phase 4	Sjogren's Syndrome	-	Total glucosides of paeony (TGP)	rscbsczuay(pzyisgzrnz) = rlojigxgvd ugelrvgyzs (qbyadtxkzo ) View more	-	08 Jun 2016